What is an emtricitabine Paragraph IV filing?
A “Paragraph IV” filing is a type of abbreviated new drug application (ANDA) certification under the U.S. Hatch-Waxman Act. It’s typically filed by a generic company when it seeks to market a generic version of an existing brand-name drug and asserts that at least one listed patent covering the brand product is invalid, unenforceable, or won’t be infringed by the proposed generic product.
For “emtricitabine,” a Paragraph IV filing would mean a generic ANDA applicant is challenging one or more patents listed for the emtricitabine brand(s) in order to launch its generic once it is legally permitted.
What happens after a Paragraph IV filing?
If the ANDA includes a Paragraph IV certification, the brand company can sue for patent infringement. That lawsuit triggers an automatic stay of generic approval in many circumstances, which can delay marketing while the litigation proceeds.
If the generic wins (or the case ends in a way that removes the stay), the generic can often enter the market sooner, subject to the remaining regulatory and exclusivity/patent landscape.
How do you find the specific emtricitabine Paragraph IV filing details?
To identify the exact emtricitabine Paragraph IV filing and the patents it targets, you generally need at least one of the following:
- The generic company name (the ANDA filer)
- The brand drug name (the reference listed drug, or RLD)
- The ANDA number
- The patent numbers listed in the Orange Book for the relevant emtricitabine product
Those details are typically found in FDA’s ANDA and “Orange Book” patent listings, along with any FDA “generic drug” approval or “patent litigation” updates tied to the case.
Which emtricitabine product is being referenced?
“Emtricitabine” can be marketed as:
- Emtricitabine-containing combination products (common in HIV therapy), and/or
- Standalone emtricitabine formulations
Paragraph IV filings are product-specific. The exact patents and the litigation posture depend on which RLD/strength/formulation the ANDA references. Without the brand name or ANDA/RLD, it’s not possible to pin down the exact filing.
What information are people usually looking for when they search “emtricitabine Paragraph IV filing”?
Searchers often want one or more of:
- The generic applicant’s identity
- The ANDA number
- The list of patents asserted/at issue (and what the certification is)
- Whether a lawsuit was filed and by whom
- Expected launch timing if/when the litigation stays lift
If you share one detail, I can narrow it to the exact filing
If you tell me any one of the following, I can help you interpret what the Paragraph IV filing means for that specific case:
- the generic company name, or
- the brand/RLD name, or
- the ANDA number, or
- the patent numbers you’ve seen mentioned